Syngene International Yönetim
Yönetim kriter kontrolleri 2/4
Syngene International's CEO is Jonathan Hunt, appointed in Jan 2016, has a tenure of 8.83 years. total yearly compensation is ₹285.33M, comprised of 50% salary and 50% bonuses, including company stock and options. directly owns 0.062% of the company’s shares, worth ₹213.43M. The average tenure of the management team and the board of directors is 6.1 years and 6.3 years respectively.
Anahtar bilgiler
Jonathan Hunt
İcra Kurulu Başkanı
₹285.3m
Toplam tazminat
| CEO maaş yüzdesi | 50.0% |
| CEO görev süresi | 8.8yrs |
| CEO sahipliği | 0.06% |
| Yönetim ortalama görev süresi | 6.1yrs |
| Yönetim Kurulu ortalama görev süresi | 6.3yrs |
Son yönetim güncellemeleri
Recent updates
Why Syngene International's (NSE:SYNGENE) Shaky Earnings Are Just The Beginning Of Its Problems
Oct 31
Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing
Jul 16These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely
Mar 28Do Syngene International's (NSE:SYNGENE) Earnings Warrant Your Attention?
Feb 14Earnings Not Telling The Story For Syngene International Limited (NSE:SYNGENE)
Jan 19Is Syngene International (NSE:SYNGENE) A Risky Investment?
Nov 19Is Now The Time To Put Syngene International (NSE:SYNGENE) On Your Watchlist?
Nov 01Syngene International (NSE:SYNGENE) Seems To Use Debt Rather Sparingly
Aug 07These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely
Apr 28Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching
Apr 06Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?
Jan 04Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet
Dec 08Is Syngene International (NSE:SYNGENE) Using Too Much Debt?
Aug 28Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate
Aug 10These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well
May 10Does Syngene International (NSE:SYNGENE) Have A Healthy Balance Sheet?
Feb 02Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?
Nov 26CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹5b |
| Jun 30 2024 | n/a | n/a | ₹5b |
| Mar 31 2024 | ₹285m | ₹143m | ₹5b |
| Dec 31 2023 | n/a | n/a | ₹5b |
| Sep 30 2023 | n/a | n/a | ₹5b |
| Jun 30 2023 | n/a | n/a | ₹5b |
| Mar 31 2023 | ₹85m | ₹85m | ₹5b |
| Dec 31 2022 | n/a | n/a | ₹4b |
| Sep 30 2022 | n/a | n/a | ₹4b |
| Jun 30 2022 | n/a | n/a | ₹4b |
| Mar 31 2022 | ₹76m | ₹76m | ₹4b |
| Dec 31 2021 | n/a | n/a | ₹4b |
| Sep 30 2021 | n/a | n/a | ₹4b |
| Jun 30 2021 | n/a | n/a | ₹4b |
| Mar 31 2021 | ₹65m | ₹65m | ₹4b |
| Dec 31 2020 | n/a | n/a | ₹4b |
| Sep 30 2020 | n/a | n/a | ₹4b |
| Jun 30 2020 | n/a | n/a | ₹4b |
| Mar 31 2020 | ₹66m | ₹66m | ₹4b |
| Dec 31 2019 | n/a | n/a | ₹4b |
| Sep 30 2019 | n/a | n/a | ₹4b |
| Jun 30 2019 | n/a | n/a | ₹3b |
| Mar 31 2019 | ₹90m | ₹47m | ₹3b |
| Dec 31 2018 | n/a | n/a | ₹3b |
| Sep 30 2018 | n/a | n/a | ₹3b |
| Jun 30 2018 | n/a | n/a | ₹3b |
| Mar 31 2018 | ₹94m | ₹47m | ₹3b |
Tazminat ve Piyasa: Jonathan's total compensation ($USD3.39M) is above average for companies of similar size in the Indian market ($USD589.84K).
Tazminat ve Kazançlar: Jonathan's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Jonathan Hunt (55 yo)
8.8yrs
Görev süresi
₹285,330,000
Tazminat
Mr. Jonathan Brittan Hunt serves as the Managing Director of Syngene International Limited since April 1, 2020. He has been the Chief Executive Officer of Syngene International Ltd. since January 2016 and...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| MD, CEO & Executive Director | 8.8yrs | ₹285.33m | 0.062% ₹ 213.4m | |
| CFO & Executive Director | 4.9yrs | ₹34.14m | 0.017% ₹ 58.6m | |
| Chief Scientific Officer | less than a year | Veri yok | 0% ₹ 0 | |
| Head of Investor Relations | no data | Veri yok | 0.0016% ₹ 5.4m | |
| Head of Legal | 5.3yrs | ₹4.72m | 0.0024% ₹ 8.2m | |
| Head of Corporate Communications | no data | Veri yok | Veri yok | |
| Chief Human Resources Officer | 1.9yrs | Veri yok | Veri yok | |
| Head of Pharmaceutical & Biopharmaceutical Development | no data | ₹10.80m | Veri yok | |
| Head of Formulations Development | no data | ₹5.50m | 0.025% ₹ 86.1m | |
| Head of IT | 8.8yrs | Veri yok | 0.00038% ₹ 1.3m | |
| Head of Clinical Development & Stability Studies | 8.8yrs | Veri yok | 0.0060% ₹ 20.7m | |
| Head of EHSS | 6.8yrs | Veri yok | 0.0093% ₹ 32.3m |
6.1yrs
Ortalama Görev Süresi
Deneyimli Yönetim: SYNGENE's management team is seasoned and experienced (6.1 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| MD, CEO & Executive Director | 7.5yrs | ₹285.33m | 0.062% ₹ 213.4m | |
| CFO & Executive Director | less than a year | ₹34.14m | 0.017% ₹ 58.6m | |
| Non-Executive Director | 24.3yrs | ₹8.28m | 0.0022% ₹ 7.6m | |
| Non-Executive Chairperson | no data | ₹9.43m | 0.0055% ₹ 18.9m | |
| Lead Independent Director | 7.3yrs | ₹8.62m | Veri yok | |
| Independent Director | 7.7yrs | ₹7.46m | 0.012% ₹ 43.1m | |
| Additional Independent Director | less than a year | Veri yok | Veri yok | |
| Independent Non Executive Director | 3.4yrs | ₹6.47m | Veri yok | |
| Non-Executive Independent Director | 10.3yrs | ₹9.12m | 0.012% ₹ 43.1m | |
| Independent Director | less than a year | Veri yok | Veri yok | |
| Additional Independent Director | 5.3yrs | ₹8.46m | Veri yok |
6.3yrs
Ortalama Görev Süresi
63yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: SYNGENE's board of directors are considered experienced (6.3 years average tenure).